Intracranial Stenosis Stents Market: as the Stryker Wingspan Stent System's FDA Humanitarian Device Exemption clearance in August 2005 for symptomatic intracranial atherosclerotic disease with 70 to 99 percent stenosis refractory to medical therapy remains the only FDA-cleared dedicated ICAD stenting system, the WEAVE postmarket surveillance trial published in Stroke in April 2019 confirming 97.4 percent event-free outcomes at 72 hours and a 2.6 percent periprocedural stroke rate beating the FDA benchmark of 4 percent validates the commercial case for on-label Wingspan use in strictly selected patients, so the WASID trial's confirmation of 23 percent annual stroke risk in 70 percent or greater ICAD stenosis patients on medical therapy alone establishes the high unmet clinical need that sustains intracranial stenting demand, and the Stryker Neuroform Atlas Stent System's FDA premarket approval in May 2019 with expanded indication in August 2020 adds the wide-neck intracranial aneurysm coiling support indication to create Stryker's dual-indication intracranial stent platform leadership.

The global intracranial stenosis stents market size was USD 1.14 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as the large and poorly treated global burden of intracranial atherosclerotic disease especially among Asian and Black populations where the annual stroke recurrence rate of 4 to 19 percent on medical therapy alone confirms high unmet clinical need, the WEAVE postmarket surveillance trial confirming 97.4 percent event-free outcomes in on-label Wingspan use that validates the commercial case for strictly selected intracranial stenting, and the expanding availability of trained neurointerventionalists at tertiary neurovascular centres enabling more centres to offer Wingspan ICAD stenting and Neuroform Atlas aneurysm coiling support. The first driving factor is the large and persistent unmet clinical need from ICAD. Intracranial atherosclerotic disease is a major cause of stroke especially prevalent among Asian and Black populations per a 2024 peer-reviewed article in Frontiers in Neurology, with a high annual stroke recurrence rate of 4 to 19 percent despite antithrombotic therapies, with large artery atherosclerosis responsible for approximately 20 percent of all ischemic strokes and approximately 50 percent of these being intracranial. The WASID trial confirmed a 23 percent annual risk of stroke in patients with 70 percent or greater ICAD stenosis on aspirin or warfarin medical therapy, establishing the high-risk patient population that may benefit from Wingspan intracranial stenting under strict on-label criteria. The second driving factor is the WEAVE trial validation of on-label Wingspan safety. The third driving factor is the Stryker Neuroform Atlas FDA premarket approval in May 2019 with expanded indication in August 2020 adding wide-neck intracranial aneurysm coiling support to Stryker's neurovascular portfolio. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way the WEAVE trial's confirmation of 2.6 percent on-label periprocedural complication rate contrasted against 23.9 percent in off-label patients creates a strict clinical evidence-based patient selection framework that simultaneously validates Wingspan use in appropriately selected patients and defines the boundary conditions under which intracranial stenting generates acceptable periprocedural risk, enabling neurointerventionalists at academic medical centres with appropriate experience and patient selection infrastructure to offer Wingspan stenting with the confidence that the on-label rate represents achievable safety. Once a neurointerventional programme establishes a structured ICAD patient selection workflow incorporating the WEAVE on-label criteria: age 22 to 80 years, symptomatic 70 to 99 percent stenosis, baseline modified Rankin Scale 3 or less, two or more strokes in the target vessel territory with at least one on medical therapy, and stenting at least 8 days after the last stroke, the per-programme Wingspan volume compounds as the neurointerventionalist team develops procedural experience and the programme develops referral infrastructure from neurology and stroke programmes in the regional catchment area. As a result, demand and revenue are concentrating at high-volume academic neurovascular centres where Stryker Wingspan's unique FDA HDE clearance for ICAD provides a regulatory moat that MicroPort Apollo, Medtronic, and other competitors cannot overcome in the US and European markets without equivalent ICAD-specific clinical evidence and regulatory approval. For instance, the phenox pEGASUS HPC anti-thrombogenic stent launched in September 2022 with an innovative HPC coating designed for patients with intracranial aneurysms and stenoses, representing active European neurovascular device innovation in anti-thrombogenic stent surface modification technology that addresses the dual-antiplatelet therapy burden following intracranial stenting. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the WEAVE trial's definitive validation of on-label Wingspan safety, which resolves the primary clinical concern that had restricted Wingspan adoption following the SAMMPRIS trial's higher stenting arm complication rates by demonstrating that in experienced hands with strict patient selection, Wingspan ICAD stenting achieves a 2.6 percent periprocedural complication rate well below the FDA benchmark, providing the evidence-based foundation that allows neurointerventional programmes to confidently offer Wingspan ICAD stenting as a legitimate treatment option for appropriately selected patients. Clinical trial validation works as a compounding demand driver because a published high-quality postmarket surveillance trial confirming safety benchmarks enables neurointerventionalists at programmes that were previously reluctant to offer Wingspan stenting to establish ICAD stenting protocols with the support of neurology colleagues and hospital quality programmes, and each new academic medical centre that establishes a Wingspan ICAD stenting programme becomes a training site for the next generation of neurointerventionalists, gradually expanding the qualified operator base over the forecast period. The WEAVE postmarket surveillance trial enrolled 152 consecutive patients who fully met the FDA on-label usage criteria at 24 hospitals, and found that the study was stopped early after interim analysis demonstrated a lower-than-expected 2.6 percent rate of periprocedural stroke, bleed, and death, with 97.4 percent of patients event-free at 72 hours, 1.3 percent having nonfatal strokes, and 1.3 percent dying, beating the FDA prespecified benchmark of 4 percent with high predictive probability. Stryker reported that on-label patients demonstrated a 2.6 percent observed rate compared to the prespecified null hypothesis rate of 9.7 percent, suggesting on-label Wingspan use may provide promising results. FDA safety communications in April 2019 confirmed that 46 additional patients outside the approved indications had a dramatically higher 23.9 percent complication rate, reinforcing strict on-label patient selection. The effect on the market is a clinical evidence foundation that enables on-label Wingspan ICAD stenting programmes at appropriately equipped and staffed academic neurovascular centres. These are some of the key factors driving revenue growth of the market.

The second driver is the structural epidemiological demand from the high and persistent ICAD stroke burden that medical therapy alone cannot adequately manage in high-risk patients, creating a treatment gap that the Wingspan Stent System is uniquely positioned to address in strictly selected patients meeting the on-label HDE criteria. High unmet clinical need works as a structural demand driver because the ICAD patient who has experienced two or more strokes while on dual antiplatelet therapy has demonstrated failure of medical management and faces a 23 percent annual stroke risk on aspirin or warfarin per WASID trial data, representing a compelling risk-benefit calculation for Wingspan stenting if the periprocedural risk is manageable with experienced operators and strict patient selection. Intracranial atherosclerotic disease is a major cause of stroke especially prevalent among Asian and Black populations per Frontiers in Neurology 2024, characterised by atherosclerotic narrowing of intracranial arteries and a high annual stroke recurrence rate of 4 to 19 percent despite antithrombotic therapies, with Hispanics, Africans, and Asians more likely to have higher ICAD rates due to varying risk factor profiles, dietary habits, and genetic factors including higher hypertension, hyperlipidaemia, and diabetes mellitus prevalence among affected populations. Large artery atherosclerosis is responsible for approximately 20 percent of all ischemic strokes with approximately 50 percent of these being intracranial per available epidemiological literature. The WASID trial enrolled patients between 1999 and 2003 comparing aspirin and warfarin for symptomatic ICAD, finding a 23 percent annual risk of stroke in patients with 70 percent or greater ICAD stenosis on medical therapy, establishing the baseline medical therapy failure rate that defines the high-risk patient population for whom Wingspan ICAD stenting represents a potentially beneficial treatment option. The effect on the market is a structural, epidemiologically-grounded demand base that is highest in Asia Pacific where ICAD prevalence in Asian populations is greatest globally. These are some of the key factors driving revenue growth of the market.

"The WEAVE trial data is the most important piece of evidence supporting commercial adoption of the Wingspan stent system because it definitively answers the clinical community's primary concern after the SAMMPRIS trial. The WEAVE 2.6% on-label rate demonstrates that in experienced hands with strict on-label patient selection, Wingspan stenting for ICAD can be performed with a complication rate well below the 4% FDA benchmark. The 23.9% off-label complication rate in the 46 additional patients who did not meet the on-label criteria is equally important, as it shows that the 2.6% on-label rate is achievable because of both patient selection and physician experience, not because of the device characteristics alone."

Clarivant Analyst Intelligence, Q1 2026

The third driver is the Stryker Neuroform Atlas Stent System's PMA approval and expanded indication creating a second commercially meaningful intracranial stent indication alongside the Wingspan ICAD HDE, establishing Stryker as the dual-indication intracranial stent leader across two distinct neurovascular patient populations that generate additive per-programme procedure volume rather than competing for the same patients. Dual-indication commercial expansion works as a market driver because the Neuroform Atlas wide-neck aneurysm coiling support indication addresses a completely different patient population from Wingspan ICAD, specifically patients with intracranial aneurysms requiring stent-assisted coil embolization where the aneurysm neck is too wide for coils to be packed without prolapsing into the parent artery, so each neurovascular catheterisation laboratory that uses both Wingspan and Neuroform Atlas generates additive per-programme revenue from two independent intracranial stent indications. Stryker's Neuroform Atlas Stent System received FDA premarket approval in May 2019 for use as an adjunct to coil embolization in the treatment of wide-neck intracranial aneurysms, comprising a self-expanding stent intended for use with detachable metal embolization coils, with the flexible and trackable delivery system designed to facilitate access through challenging neurovascular anatomy. The FDA expanded the Neuroform Atlas indication in August 2020, broadening the clinical application for wide-neck intracranial aneurysm treatment beyond the initial May 2019 scope. phenox GmbH introduced the pEGASUS HPC anti-thrombogenic stent in September 2022 featuring an HPC coating that reduces platelet activation and thrombus formation on the stent surface, representing European innovation in anti-thrombogenic intracranial stent surface modification that addresses the in-stent thrombosis risk during the dual antiplatelet therapy endothelialisation period. The effect on the market is a structural commercial expansion of the intracranial stent addressable market beyond ICAD into the wide-neck aneurysm indication, with Stryker holding dual-indication leadership across both major intracranial stent revenue streams. These are some of the key factors driving revenue growth of the market.

However, the intracranial stenosis stents market faces adoption constraints from the strict Wingspan HDE labeling limiting the on-label eligible patient population, the demanding neurointerventionalist training requirement restricting adoption to high-volume academic medical centres, and periprocedural haemorrhagic risk from dual antiplatelet therapy following stent placement. The SAMMPRIS and VISSIT randomized controlled trials showing higher complication rates in stenting arms versus aggressive medical management have restricted physician confidence in intracranial stenting for ICAD beyond strict on-label HDE criteria, and the strict Wingspan HDE labeling means that ICAD patients with high recurrent stroke risk who do not meet all six on-label criteria, particularly the two-or-more-strokes-on-medical-therapy criterion, cannot receive on-label Wingspan stenting and must continue on medical therapy despite the demonstrated 23 percent annual medical therapy stroke risk. The demanding neurointerventionalist training requirement is a second constraint, since the WEAVE trial's 23.9 percent off-label complication rate versus 2.6 percent on-label reflects not just patient selection but also operator experience, confirming that safe Wingspan outcomes depend on both strict patient selection and high neurointerventionalist procedural experience that restricts adoption to academic medical centres with experienced neurointerventional faculty and cannot be safely propagated to community neurovascular programmes without the equivalent training infrastructure. Periprocedural haemorrhagic risk of dual antiplatelet therapy is a third constraint, since the mandatory dual antiplatelet therapy required after intracranial stent placement to prevent in-stent thrombosis during endothelialisation carries its own haemorrhage risk in a patient population that has already suffered cerebrovascular events, creating a net clinical benefit calculation that limits Wingspan to patients where the 23 percent annual medical therapy stroke risk clearly dominates the combined stenting procedural and antiplatelet haemorrhage risk. These factors substantially limit intracranial stenosis stents market growth over the forecast period.

Based on product type, the global intracranial stenosis stents market is segmented into self-expanding stents, balloon-expandable stents, flow diverters, and embolization coil support stents. Self-expanding stents for ICAD led by the Stryker Wingspan Stent System hold the largest revenue share at approximately 45 percent of 2025 market revenue through Wingspan's unique status as the only FDA HDE-cleared dedicated intracranial atherosclerotic disease stenting system for 70 to 99 percent symptomatic stenosis. Flow diverters including Medtronic Pipeline Vantage for complex large intracranial aneurysms are expected to register the fastest revenue growth rate in the global intracranial stenosis stents market over the forecast period at approximately 8 percent CAGR, driven by expanding indications and growing neurointerventionalist experience with flow diversion technique for large, giant, and complex aneurysms requiring flow diversion rather than direct coil embolization. Embolization coil support stents including Stryker Neuroform Atlas and Codman Enterprise 2 represent the established wide-neck aneurysm indication segment at approximately 21 percent of market revenue.

Based on indication, the global intracranial stenosis stents market is segmented into intracranial atherosclerotic disease stenosis and wide-neck intracranial aneurysms. ICAD stenosis accounts for the largest revenue share at approximately 45 percent of 2025 market revenue through the Wingspan HDE platform as the primary on-label ICAD stenting system globally and the MicroPort Apollo balloon-expandable ICAD stent in Asia Pacific markets. Wide-neck intracranial aneurysms are expected to register rapid revenue growth, driven by Stryker Neuroform Atlas PMA May 2019 and August 2020 expanded indication, Codman Enterprise 2 aneurysm stent, Medtronic Pipeline Vantage flow diverter for large and complex aneurysms, and growing neurointerventionalist familiarity with stent-assisted coil embolization technique for wide-neck aneurysm management at high-volume academic neurovascular centres.

Based on regional analysis, the intracranial stenosis stents market in North America accounted for largest revenue share in 2025 at approximately 36 percent of global revenue. The Stryker Wingspan HDE platform anchors North American ICAD stenting at academic medical centres and major stroke neurovascular programmes where trained neurointerventionalists have established WEAVE on-label patient selection workflows. Stryker Neuroform Atlas premarket approval May 2019 and expanded indication August 2020 establish Stryker as the dual-indication leader across both ICAD and wide-neck aneurysm stenting at North American neurovascular catheterisation laboratories. FDA safety communications in April 2019 confirming ongoing engagement with Wingspan on-label use guidance sustain clinical attention to appropriate patient selection at US neurovascular centres.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national intracranial stenosis stent markets within Europe. Stryker Wingspan, Neuroform Atlas, Medtronic Pipeline Vantage, and Codman Enterprise 2 are the primary CE-marked intracranial stent platforms at European academic neurosurgery and neurointerventional radiology centres. phenox GmbH introduced the pEGASUS HPC anti-thrombogenic stent in September 2022 for ICAD and aneurysms, confirming active European intracranial stent innovation from specialty neurovascular device companies with anti-thrombogenic coating technology addressing the dual antiplatelet therapy burden following stent placement.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. China, Japan, South Korea, India, and Australia represent the five largest national intracranial stenosis stent markets. Asia Pacific hosts the world's highest prevalence of ICAD-related stroke due to the high ICAD rates in Asian populations confirmed in Frontiers in Neurology 2024, with Hispanics, Africans, and Asians more likely to have higher ICAD rates due to varying risk factor profiles and genetic factors. China's MicroPort Scientific Corporation competes in the Chinese ICAD market with the Apollo Intracranial Stent System as a balloon-expandable alternative to Wingspan, and China's rapidly expanding neurovascular interventional infrastructure at tertiary stroke centres and growing neurointerventionalist training programmes support Asia Pacific market growth above the global average. The high ICAD prevalence in Asian populations with smaller, more distal intracranial vessel involvement and more calcified lesions creates specific procedural challenges that balloon-expandable platforms like MicroPort Apollo may address better than self-expanding platforms in certain Asian ICAD anatomical configurations.

The markets in Latin America and Middle East and Africa are expected to register moderate revenue growth rates over the forecast period. Brazil and Mexico represent primary Latin American commercial markets with private hospital neurovascular centres in major metropolitan areas. Saudi Arabia and the UAE represent primary Middle East commercial markets, with GCC investment in neurovascular and stroke intervention capabilities at specialised cardiac and neurovascular centres under Vision 2030 supporting growing intracranial stent adoption in the region over the forecast period as trained neurointerventionalist capacity expands at GCC academic medical centres.